Gemcitabine, Cisplatin and Immunotherapy: A Promising Mix for Advanced Bladder Cancer – Guru Sonpavde & Matthew Galsky
Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study’s design, focusing on comparing gemcitabine cisplatin with and without nivolumab in cisplatin-eligible patients. He highlights the study’s backdrop, noting previous trials and the potential immunogenic superiority of cisplatin. Dr. Galsky…